Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000899243-21-018116
Filing Date
2021-05-04
Accepted
2021-05-04 16:31:20
Documents
1
Period of Report
2020-12-23

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 14827
  Complete submission text file 0000899243-21-018116.txt   16219
Mailing Address 1030 MASSACHUSETTS AVENUE SUITE 210 CAMBRIDGE MA 02138
Business Address 1030 MASSACHUSETTS AVENUE SUITE 210 CAMBRIDGE MA 02138 617-952-0555
Werewolf Therapeutics, Inc. (Issuer) CIK: 0001785530 (see all company filings)

EIN.: 823523180 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 1030 MASSACHUSETTS AVENUE SUITE 210 CAMBRIDGE MA 02138
Business Address
Asanuma Sakae (Reporting) CIK: 0001857822 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40366 | Film No.: 21889019